| Literature DB >> 33083625 |
Wael I Mortada1, Amira Awadalla2, Sherry M Khater3, Nashwa M Barakat4, Sherif M Husseiny5, Ahmed A Shokeir2.
Abstract
OBJECTIVES: Pomegranate juice (PJ) is rich in important compounds with anti-cancer activities. This study aims to investigate the preventive effect of pomegranate juice (PJ) against bladder cancer (BC).Entities:
Keywords: Antioxidant; Bladder cancer; Cancer research; Chemoprevention; Flavonoid; Genetics; Molecular biology; Oxidative stress; Polyphenol; Pomegranate juice; Toxicology
Year: 2020 PMID: 33083625 PMCID: PMC7551357 DOI: 10.1016/j.heliyon.2020.e05192
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Figure 1Scheme of the animal study design.
Body weight and bladder/body weight ratio among the study groups.
| Normal group | PJ group | cancer-induced group | cancer-prevented group | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Initial body weight (g) | 227.3 ± 3.6 | 229.5 ± 3.4 | 226.8 ± 4.0 | 228.0 ± 2.3 | 0.48 | 0.66 | 0.57 | 0.61 | 0.70 |
| Final body weight (g) | 315.1 ± 5.9 | 321.4 ± 6.4 | 296.6 ± 7.9 | 311.5 ± 8.4 | 0.37 | 0.29 | 0.40 | 0.66 | 0.42 |
| Bladder/body weight ratio (%) | 0.03 ± 0.01 | 0.03 ± 0.01 | 0.18 ± 0.06 | 0.06 ± 0.02 | <0.001 | 0.80 | <0.001 | <0.01 | <0.001 |
p1: Normal vs PJ vs cancer-induced vs cancer-prevented groups.
p2: Normal vs PJ.
p3: Normal vs cancer-induced.
p4: Normal vs cancer-prevented.
p5: cancer-induced vs cancer-prevented.
Results of histopathological and immunohistochemistry examinations.
| Variable | Normal group | PJ group | cancer-induced group | cancer-prevented group | ||||
|---|---|---|---|---|---|---|---|---|
| n (%) | ||||||||
| Neoplastic lesions | ||||||||
| Single | 0 (0) | 0 (0) | 13 (65) | 0 (0) | <0.001 | <0.001 | - | <0.001 |
| Multiple | 0 (0) | 0 (0) | 7 (35) | 0 (0) | <0.001 | <0.001 | - | <0.001 |
| Mucosal changes | ||||||||
| Degeneration of umbrella cells | 0 (0) | 0 (0) | 10 (50) | 0 (0) | <0.001 | <0.001 | - | <0.001 |
| Mucosal thickness | 0 (0) | 0 (0) | 20 (100) | 5 (25) | <0.001 | <0.001 | <0.01 | <0.001 |
| Dysplasia | ||||||||
| Mild | 0 (0) | 0 (0) | 10 (50) | 5 (25) | <0.001 | <0.001 | <0.01 | <0.01 |
| Moderate | 0 (0) | 0 (0) | 10 (50) | 0 (0) | <0.001 | <0.001 | - | <0.001 |
| Inflammation | 0 (0) | 0 (0) | 20 (100) | 5 (25) | <0.001 | <0.001 | <0.01 | <0.001 |
| Intramucosal hemorrhage | 0 (0) | 0 (0) | 20 (100) | 5 (25) | <0.001 | <0.001 | <0.01 | <0.001 |
| Lamina propria changes | ||||||||
| Tumor invasion | 0 (0) | 0 (0) | 10 (50) | 0 (0) | <0.001 | <0.001 | - | <0.001 |
| Marked eosinophilic infiltrate | 0 (0) | 0 (0) | 20 (100) | 5 (25) | <0.001 | <0.001 | <0.01 | <0.001 |
| Congested capillaries | 0 (0) | 0 (0) | 20 (100) | 5 (25) | <0.001 | <0.001 | <0.01 | <0.001 |
| p53 immunostaining | ||||||||
| Negative (grade 0 intensity) | 20 (100) | 20 (100) | 0 (0) | 10 (50) | <0.001 | <0.001 | <0.001 | <0.001 |
| Positive | ||||||||
| Grade 1 intensity | 0 (0) | 0 (0) | 0 (0) | 10 (50) | <0.001 | - | <0.001 | <0.001 |
| Grade 2 intensity | 0 (0) | 0 (0) | 10 (50) | 0 (0) | <0.001 | <0.001 | - | <0.001 |
| Grade 3 intensity | 0 (0) | 0 (0) | 10 (50) | 0 (0) | <0.001 | <0.001 | - | <0.001 |
p1: Normal vs PJ vs cancer-induced vs cancer-prevented groups.
p2: Normal vs cancer-induced.
p3: Normal vs cancer-prevented.
p4: cancer-induced vs cancer-prevented.
Figure 2Microscopic examination using H & E. A: Papillary hyperplasia with mild dysplasia in the cancer-induced group. B: Papillary hyperplasia without any dysplasia in the cancer-prevented group. C: GI papillary transition cell carcinoma infiltrating lamina propria in cancer-induced group. D: Proliferative lesion formation (Brunn's nests) in the cancer-prevented group. E: Marked mucosal dysplasia along whole mucosal thickness and mild edema in lamina propria of cancer-induced group. F: Increased mucosal thickness with small focus of squamous metaplasia (intercellular desmosomes) in the cancer-prevented group.
Figure 3p53 immunostaining of urinary bladder samples. A: negative immunostaining in the normal group. B: Moderate to marked immunostaining intensity in >50% of cells of cancer-induced group. C: Mild immunostaining intensity in <9% of cells of cancer-prevented group
Results of gene expression.
| Gene | Relative quantification of genes | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Normal group | PJ group | Cancer-induced group | Cancer-prevented group | ||||||
| IL-6 | 1.26 ± 0.06 | 1.16 ± 0.12 | 5.03 ± 0.34 | 2.41 ± 0.35 | <0.001 | <0.001 | <0.01 | <0.001 | |
| TNF-α | 1.21 ± 0.09 | 1.01 ± 0.06 | 8.10 ± 0.38 | 3.99 ± 0.38 | <0.001 | <0.001 | <0.001 | <0.001 | |
| HIF | 1.02 ± 0.10 | 0.98 ± 0.07 | 3.08 ± 0.53 | 1.42 ± 0.22 | <0.001 | <0.001 | <0.05 | <0.001 | |
| TP53 | 1.35 ± 0.10 | 1.26 ± 0.06 | 10.35 ± 0.36 | 4.64 ± 0.34 | <0.001 | <0.001 | <0.001 | <0.001 | |
p1: Normal vs PJ vs cancer-induced vs cancer-prevented groups.
p2: Normal vs cancer-induced.
p3: Normal vs cancer-prevented.
p4: cancer-induced vs cancer-prevented.
Markers of oxidative stress.
| Variable | Normal group | PJ group | Cancer-induced group | Cancer-prevented group | ||||
|---|---|---|---|---|---|---|---|---|
| MDA (nmol g−1) | 60.3 ± 6.5 | 61.4 ± 7.4 | 201.9 ± 28.5 | 66.2 ± 8.3 | <0.001 | <0.001 | 0.351 | <0.001 |
| CAT (U g−1) | 19.4 ± 3.0 | 20.5 ± 3.8 | 11.9 ± 2.2 | 21.6 ± 4.0 | <0.001 | <0.001 | 0.243 | <0.001 |
| GSH (U g−1) | 125.1 ± 13.3 | 128.5 ± 14.1 | 36.1 ± 5.0 | 111.8 ± 17.4 | <0.001 | <0.001 | 0.174 | <0.001 |
| SOD (U g−1) | 13.1 ± 2.8 | 13.4 ± 3.3 | 2.6 ± 0.6 | 10.2 ± 2.0 | <0.001 | <0.001 | 0.109 | <0.001 |
p1: Normal vs PJ vs cancer-induced vs cancer-prevented groups.
p2: Normal vs cancer-induced.
p3: Normal vs cancer-prevented.
p4: cancer-induced vs cancer-prevented.